Dyne Therapeutics received an "Outperform" rating from Oppenheimer with a $47.00 price target.
Dyne Therapeutics (NASDAQ:DYN) received an "Outperform" rating from Oppenheimer with a $47.00 price target, according to a report published Monday. The company has also received overweight and buy ratings from other analysts, including Piper Sandler, Chardan Capital, HC Wainwright, and Stifel Nicolaus. Morgan Stanley initiated coverage on DYN with an overweight rating and a $40.00 price objective.
May 09, 2024
4 Articles